Cosmos Health (COSM) filed a patent application for a treatment for multiple sclerosis.
This milestone highlights the partnership with Cloudpharm and the National Hellenic Research Foundation, supported by the pharma patent expert team at NLO Group, Cosmos Health said Wednesday in a statement.
The patent is based on data from Cosmos Health's artificial intelligence-powered Cloudscreen drug repurposing platform.
"Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action," according to the statement.
MS is an autoimmune disorder that affects the central nervous system.
Price: 0.7096, Change: +0.0096, Percent Change: +1.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.